in Health care
Lorlatinib is safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma, research shows
Neuroblastoma is an aggressive pediatric cancer that develops from early nerve cells, often appearing as a solid tumor in the chest or abdomen. The disease accounts for up to 10% of childhood cancer deaths, and survival rates are low – less than 50% of patients with the disease survive, and there is still no known […] More
